Answers are grounded in this paper and cite their sources.
FDA-approved intravesical gemcitabine shows effectiveness against BCG-unresponsive tumors in bladder cancer.
The FDA has approved Inlexzo, a gemcitabine intravesical system, for treatment of Bacillus Calmette- Guérin (BCG)-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ, with or without papillary tumors. The Inlexzo system is placed into the bladder to deliver gemcitabine for 3 weeks.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: